Sign in
CompletedPhase 4

Cytisine for Smoking Cessation

Key facts

Who runs it
Centre for Addiction and Mental Health
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
20 people enrolled
Started
8 Feb 2023
Ended
12 Dec 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cytisine
  • Placebo
Record updated
27 February 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Aged 18-65 years
  • Have TUD assessed by structured clinical interview for DSM-5
  • Have past year AUD (active) assessed by structured clinical interview for DSM-5
  • Report daily cigarette consumption in past month and expired carbon monoxide (CO) measurement ≥10ppm at screening
  • Have Fagerstrom Test of Nicotine Dependence (FTND55) score ≥4
  • Have motivation to quit within 30 days i.e. Contemplation Ladder56 score ≥7
  • Be willing and able to comply with all study procedural and assessment demands
  • Be able to provide voluntary written informed consent

Who cannot take part

  • Have a serious unstable psychiatric or medical condition preventing participation in the trial. This includes some forms of schizophrenia, ischemic heart disease, heart failure, arterial hypertension (systolic BP above 150; diastolic BP above 100), cerebrovascular diseases, occlusion of blood vessels, kidney and/or liver disease, hyperthyroidism, ulcer, diabetes, Chromaffin tumours of the adrenal medulla, and gastroesophageal reflux disease (GERD)
  • Report prolonged smoking abstinence in the past month preceding screening
  • Be using other smoking cessation aids
  • Enrolled in another smoking cessation program
  • Be pregnant, breastfeeding, or intending to become pregnant or breastfeed
  • Exhibit suicidal thoughts or behavior in the past month
  • Enrolled in another study which would interfere with study procedures or represent a potential risk to the participant

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the safety and effectiveness of cytisine as a smoking cessation treatment in individuals with concurrent alcohol use disorder.

The 2 groups in the trial

  • CytisineTreatment being tested

    Cytisine will be given as 1.5 mg tablet formulations for 25 days. The following treatment schedule will be followed: * Days 1 to 3: 1.5 mg taken every 2 hours (6 pills (9 mg)/day) * Days 4 to 12: 1.5 mg taken every 2.5 hours (5 pills (7.5 mg)/day) * Days 13 to 16: 1.5 mg taken every 3 hours (4 pills (6 mg)/day) * Days 17 to 20: Taper down to 1 tablet every 5 hours (3 pills (4.5 mg)/day) * Days 21 to 25: Taper down to 1-2 tablets daily (1.5-3 mg/day)

  • PlaceboPlacebo, for comparison

    Placebo will be given following the same schedule as the Cytisine Arm.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Cytisine: Testing Its Potential as a Therapeutic Strategy for Smoking Cessation Among People With Concurrent Alcohol Use Disorder
Record updated
27 February 2026